Compare
OnKure Therapeutics, Inc. vs Lifevantage Corp vs Rallybio Corp vs AN2 Therapeutics, Inc.
| Latest fiscal year | OnKure Therapeutics, Inc. OKUR | Lifevantage Corp LFVN | Rallybio Corp RLYB | AN2 Therapeutics, Inc. ANTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $182.59M | $858.0K | n/a |
| Revenue growth (YoY) | n/a | -20.1% | +34.9% | n/a |
| Gross margin | n/a | 77.6% | n/a | n/a |
| Operating margin | n/a | 3.3% | n/m | n/a |
| Net margin | n/a | 2.8% | n/m | n/a |
| Net income | -$59.52M | $5.07M | -$8.98M | -$35.17M |
| EPS (Diluted) | -$4.40 | $0.40 | -$1.59 | -$1.16 |
| Operating cash flow | -$51.83M | $10.24M | -$29.81M | -$29.83M |
| Free cash flow | -$51.87M | $6.67M | n/a | n/a |
| Cash & equivalents | $59.05M | n/a | $31.37M | $19.94M |
| Total assets | $62.12M | $62.11M | $62.26M | $61.95M |
| Total liabilities | $5.93M | $28.52M | $4.30M | $8.89M |
| Shareholders' equity | $56.18M | $33.59M | $57.96M | $53.06M |
| Return on year-end equity | -105.9% | 15.1% | -15.5% | -66.3% |
| Shares outstanding | n/a | 12.52M | 5.28M | 27.41M |
Revenue, most recent five fiscal years
| Fiscal year | OnKure Therapeutics, Inc. | Lifevantage Corp | Rallybio Corp | AN2 Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2024-12-31 | $182.59M Ended 2026-06-30 | $858.0K Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $228.53M Ended 2025-06-30 | $636.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $200.16M Ended 2024-06-30 | n/a | n/a |
| 3 years earlier | n/a | $213.40M Ended 2023-06-30 | n/a | n/a |
| 4 years earlier | n/a | $206.36M Ended 2022-06-30 | n/a | n/a |